AzTrials
AzTrials

Lower Respiratory Tract Infection (LRTI)NCT07807917

Quality of Life After Lower Respiratory Tract Infection

An observational study of Lower Respiratory Tract Infection (LRTI) and Chest Infection, run by University of Nottingham at 1 site in United Kingdom.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Lower respiratory tract infections (LRTIs) are any infections below the vocal cords which affect the airways or the air sacs in the lungs. They include pneumonia, bronchitis and chest infections and are usually caused by viruses such as influenza, COVID-19 or Respiratory Syncytial Virus (RSV), or by bacteria such as… Read more about this study

Who is it for?
Ages 18 years and older
How many people
200 participants
Where
1 siteUnited Kingdom
Study dates
Sep 2026to Sep 2028
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants will be recruited from the adult respiratory wards at Nottingham City Hospital as the majority of patients with a primary diagnosis of lower respiratory tract infection are admitted to these wards.

Who may be able to join

  • Adults aged ≥18years (no upper age limit).
  • Treated by attending physician as lower respiratory tract infection/community-acquired pneumonia, regardless of microbiologically-confirmed pathogen.
  • Ability to give informed consent or appropriate consultee available to give advice.

Who cannot join

  • Hospital admission within 14 days preceding the index admission
  • Post-obstructive pneumonia secondary to Lung Cancer
  • Patients treated for active Tuberculosis (TB)
  • Receiving palliative treatment only
  • Unable to understand written or spoken English
  • Presumed to be unable to answer the questionnaires over the follow-up period.
  • Exacerbations of chronic lung disease such as asthma, COPD or bronchiectasis.
  • Previously enrolled in the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jhon Galindo-Rodriguez contact

Jhon.Galindo-Rodriguez@nottingham.ac.uk

United Kingdom1 site
  • Nottingham City Hospital

    Nottingham, NG5 1PB

    Professor Wei Shen Lim, +44 (0)115 924 9924, weishen.lim@nhs.net

Other trials in United Kingdom

About this study

Official title: Evaluation of Health-Related Quality of Life in Adults Hospitalised With Lower Respiratory Tract Infection

Lower respiratory tract infections (LRTIs) are any infections below the vocal cords which affect the airways or the air sacs in the lungs. They include pneumonia, bronchitis and chest infections and are usually caused by viruses such as influenza, COVID-19 or Respiratory Syncytial Virus (RSV), or by bacteria such as pneumococcus. LRTIs are common, particularly in older adults; in the UK approximately 15% of people aged over 65 years will experience a chest infection each year and many of those will need in-patient treatment.

People who have had a chest infection may experience slow recovery after their infection. Patients often report that their quality of life is worse after an infection (for example persistent fatigue, reduced physical functioning, and mental health challenges) and this can affect the return to usual activities. However, there have not been many studies that have looked at how the quality of life changes in the months following a chest infection, and why some people take longer to recover.

In this study, the investigators will use a well-recognised questionnaire to measure quality of life for up to one year in adults who have been admitted to hospital with a chest infection. The findings will help the investigators to assess how long-term quality of life is affected after a chest infection and what factors may affect it. The results will also permit calculation of the costs faced by patients during recovery from a chest infection, in financial terms. These results will feed into studies looking at ways of improving recovery after a chest infection.

Read the detailed description

Acute lower respiratory tract infections (LRTIs) are a group of infections affecting the respiratory tract below the level of the larynx, including pneumonia, acute bronchitis, bronchiolitis, acute infective exacerbations of chronic obstructive pulmonary disease (COPD).

In those who survive their initial episode of LRTI, recovery may be slow with adverse outcomes which may last months or even years after the initial episode and have implications for patients, their families and health care resources. A recent prospective cohort study in the U.S. (PNEUMO) reported that at 6 months after hospitalisation with community-acquired pneumonia (CAP) and compared to their pre-hospitalisation status, 12.8% of participants had lost the ability to perform at least one basic activity of daily living (ADL), 22.0% lost the ability to perform at least one instrumental ADL, 41.6% suffered cognitive impairment, 58.7% had loss of employment, and 23.6% had decreased quality of life (Han et al 2025). Additionally pneumonia patients have high rates of readmission to hospital, which in turn is associated with significant inpatient mortality (Lawrence et al 2023), high rates of primary care consultation within 7 days of discharge (Baskaran et al 2021), increased risk of cardiovascular events and heart failure (Eurich et al 2017; Violi et al 2017), recurrent pneumonia (Baskaran et al 2022) and persistent symptoms (Pick et al 2019).

LRTIs therefore heavily impact patients, their families and carers, and the use of healthcare resources. Measuring the quality of life in patients hospitalised with acute LRTIs for up to one year after their discharge is an important component in the broader assessment of the cost of LRTIs in the UK, but long-term quality of life data in these patients are limited.

Every individual's experience of recovery from pneumonia is unique reflecting the complex interplay between their clinical characteristics, existing co-morbidities, frailty, physical and mental status, illness severity, and underlying causative micro-organism. There are few long-term data on outcomes which are important to patients following an episode of LRTI, including patient-perceived quality of life. It is therefore important to study this outcome and to identify those factors which may be associated with quality-of life measures in order to: a) gain a broader picture of the impact of LRTI on patients themselves; b) inform future trials assessing interventions aimed at improving patients' quality of life; c) to feed into analyses of the health economic costs of LRTIs.

The purpose of this study is to gain a better understanding of how health-related quality of life is affected in people who are hospitalised after a LRTI. The primary objective is to document health states and utility indexes for hospitalised LRTI patients and their evolution over the course of one year after the initial episode. The secondary objective is to evaluate associations between patient characteristics and their hospital stay with their health-related quality of life.

Participants will be recruited when they are almost ready to be sent home from hospital. Informed consent will be obtained prior to participation (or for those lacking capacity to provide consent, a consultee acting on their behalf will complete a declaration form). Before discharge participants will be asked to complete the EQ-5D-5L health-related quality of life questionnaire . After discharge from hospital, participants will complete the same questionnaire at one month, three months, six months and one year after discharge. Questionnaires will be administered by telephone, digitally (email form) or by post.

Descriptive statistics will be conducted at each time point (discharge, 1, 3, 6, 12 months):

  1. EQ-5D-5L profiles: Number and proportion at each level (1-5) for each dimension.
  2. Ceiling/floor effects: Proportion at ceiling (11111) and floor (severe problems on ≥3 dimensions) reported at each timepoint.
  3. Utility values: Mean, Standard Deviation (SD), Standard Error (SE), median, Interquartile Range (IQR), min, max, and n.
  4. VAS scores: Mean, SD, median, IQR, min, max (descriptive only).
  5. Change scores: Mean change from baseline to each follow-up, with 95% Confidence Interval (CI).
  6. Population comparison: Utility decrement from age-sex matched norms at each time point.

Quality-Adjusted Life Years (QALYs) will be calculated using area-under-the-curve with trapezoidal rule and linear interpolation:

  1. Time zero: Hospital discharge date.
  2. Intervals: Discharge→1 month, 1→3 months, 3→6 months, 6→12 months. Actual days used.
  3. Formula: QALY per interval = [(Ustart + Uend) / 2] × time in years. Total QALYs =
  • (QALY_intervals)
  1. Mortality: Deaths contribute QALYs to date of death (utility = 0 thereafter).
  2. QALY loss: Calculated as the difference between expected and observed QALYs over 12 months. Expected QALYs derived from age-sex matched English population norms using adjusted limited dependent variable mixture models (ALDVMM) with EQ-5D-5L responses mapped to 3L using Hernández Alava algorithm.

Health state utility values reported by severity tier and time point will serve as inputs for cost-effectiveness models, where survival is incorporated through model structure using transition probabilities derived from the linked CPRD-HES cohort.

All cohorts will be stratified by age, sex, severity tier, diagnostic category, index of Multiple Deprivation quintile, number of co-morbidities, ECOG Performance Status, CURB-65 score.

To model utility trajectories over time and identify predictors of recovery, the investigators will use mixed-effects linear regression with random intercepts. Fixed effects: time, age, sex, severity tier, performance status, comorbidity count. Time × severity interaction explored to assess differential recovery rates. Predicted 12-month utilities derived from model.

Because EQ-5D utility values have an upper limit and many patients may report full health at follow-up, the investigators will check whether the model fits the data and produces realistic predicted values. If predictions fall outside the valid range or the model performs poorly, alternative approaches (such as Tobit regression, generalised linear models with clustered responses, or two-part models) will be explored in sensitivity analyses.

Missing data: Completion rates will be reported by timepoint and baseline characteristics compared between completers and non-completers. The following sensitivity analyses for missing data will be performed (a) multiple imputation by chained equations (MICE) conditional on baseline characteristics and severity tier, with last observation carried forward (LOCF) as conservative comparator; (b) Complete case: restricted to participants with EQ-5D-5L data at all five timepoints.

Keywords
Lower respiratory tract infection, Chest infection, Pneumonia, Quality of life, EQ-5D-5L
Medical subject headings
Pneumonia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07807917
Study groupRoleWhat they receive
Lower respiratory tract infectionAdults hospitalised with a lower respiratory tract infection (low, moderate or severe severity).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in health state utility values over one year

    Health state utility values calculated from EQ-5D-5L profiles using preference-based value sets pre-discharge and at 1, 3, 6 and 12 months post-discharge.

    Measured: From enrolment to one year post-discharge from hospital

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Sep 2026
  2. Study startSep 2026 (estimated)
  3. Primary completionSep 2028 (estimated)
  4. Study completionSep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07807917
Sponsor's protocol ID
26019
Status last verified
Aug 2026
First submitted
1 Sep 2026
Last updated
30 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Pick HJ, Bolton CE, Lim WS, McKeever TM. Patient-reported outcome measures in the recovery of adults hospitalised with community-acquired pneumonia: a systematic review. Eur Respir J. 2019 Mar 18;53(3):1802165. doi: 10.1183/13993003.02165-2018. Print 2019 Mar.

    PubMed 30635298
  • Baskaran V, Lim WS, McKeever TM. Effects of tobacco smoking on recurrent hospitalisation with pneumonia: a population-based cohort study. Thorax. 2022 Jan;77(1):82-85. doi: 10.1136/thoraxjnl-2020-216494. Epub 2021 Jun 18.

    PubMed 34145048
  • Violi F, Cangemi R, Falcone M, Taliani G, Pieralli F, Vannucchi V, Nozzoli C, Venditti M, Chirinos JA, Corrales-Medina VF; SIXTUS (Thrombosis-Related Extrapulmonary Outcomes in Pneumonia) Study Group. Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia. Clin Infect Dis. 2017 Jun 1;64(11):1486-1493. doi: 10.1093/cid/cix164.

    PubMed 28205683
  • Baskaran V, Pearce F, Harwood RH, McKeever TM, Lim WS. Primary care consultations after hospitalisation for pneumonia: a large population-based cohort study. Br J Gen Pract. 2021 Mar 26;71(705):e250-e257. doi: 10.3399/BJGP.2020.0890. Print 2021 Apr.

    PubMed 33753348
  • Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Risk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-up. BMJ. 2017 Feb 13;356:j413. doi: 10.1136/bmj.j413.

    PubMed 28193610
  • Lawrence H, McKeever TM, Lim WS; British Thoracic Society. Readmission following hospital admission for community-acquired pneumonia in England. Thorax. 2023 Dec;78(12):1254-1261. doi: 10.1136/thorax-2022-219925. Epub 2023 Jul 31.

    PubMed 37524392
  • Han JH, Resser JJ, Baughman A, Grijalva CG, Johnson J, Miller KF, Roberts CS, Johnson KD, Weiss T, Self WH; PNEUMO Study Investigators. Community-acquired pneumonia in hospitalized adults: long-term morbidities and their risk factors. BMC Infect Dis. 2025 Jul 1;25(1):826. doi: 10.1186/s12879-025-11186-w.

    PubMed 40597744

Questions about this trial

What is this clinical trial studying?

An observational study of Lower Respiratory Tract Infection (LRTI) and Chest Infection, run by University of Nottingham at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Professor Tricia McKeever (+44 (0)115 8231721, tricia.mckeever@nottingham.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in health state utility values over one year (time frame: From enrolment to one year post-discharge from hospital). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07807917, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in